Gene therapy for heart failure

Semin Thorac Cardiovasc Surg. Winter 2005;17(4):343-7. doi: 10.1053/j.semtcvs.2005.09.002.

Abstract

Congestive heart failure (CHF) remains a leading cause of morbidity and mortality in the United States and in many other countries. Current heart failure therapies, including multidrug treatment regimens, biventricular pacing, and mechanical support such as left ventricular assist devices, are often hindered by limited benefits or significant associated procedural complications or side effects. Therefore, new forms of treatment, which could ideally target the underlying biological processes affecting the ailing cardiomyocyte, would be of significant potential benefit to the population of individuals with CHF. Gene transfer strategies, including modification of cellular contractile signaling and regulatory pathways, represent a promising new form of such biologic therapy for heart disease.

Publication types

  • Review

MeSH terms

  • Adenylyl Cyclases / metabolism
  • Animals
  • Calcium-Binding Proteins / physiology
  • Calcium-Transporting ATPases / physiology
  • Genetic Therapy*
  • Heart Failure / metabolism
  • Heart Failure / physiopathology
  • Heart Failure / therapy*
  • Humans
  • Parvalbumins / metabolism
  • Peptides / pharmacology
  • Peptides / therapeutic use
  • Rats
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • S100 Proteins / metabolism
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases

Substances

  • Calcium-Binding Proteins
  • Parvalbumins
  • Peptides
  • Recombinant Proteins
  • S100 Proteins
  • beta-adrenergic receptor kinase inhibitory peptide
  • phospholamban
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • Adenylyl Cyclases
  • Calcium-Transporting ATPases